Trial Profile
Efficacy and Safety of Cryopreserved Formulation of Autologous CD34+ Hematopoietic Stem Cells Transduced Ex Vivo With Elongation Factor 1 Alpha Shortened (EFS) Lentiviral Vector Encoding for Human ADA Gene in Subjects With Severe Combined Immunodeficiency Due to ADA Deficiency
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Aug 2022
Price :
$35
*
At a glance
- Drugs Simoladagene autotemcel (Primary) ; Busulfan; Elapegademase
- Indications Adenosine deaminase deficiency
- Focus Therapeutic Use
- Acronyms UCLA Cryo Study
- Sponsors Orchard Therapeutics
- 11 May 2021 Results (n=50) from NCT01852071, NCT02999984, and NCT01380990 assessing overall and event-free survival in autologous Ex Vivo Lentiviral Gene Therapy for Adenosine Deaminase Deficiency, published in the New England Journal of Medicine
- 11 May 2021 Data from three Phase 1/2 clinical studies (n=40), and a compassionate use program (n=10) presented in an Orchard Media Release.
- 11 May 2021 According to an Orchard Therapeutics media release, data from three Phase 1/2 clinical studies (n=40), and a compassionate use program (n=10) published in the New England Journal of Medicine (NEJM) .